# Managed Access Programs for SEG101, Crizanlizumab

> **NCT03720626** · — · AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** crizanlizumab

## Key facts

- **NCT ID:** NCT03720626
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03720626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03720626, "Managed Access Programs for SEG101, Crizanlizumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03720626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*